Lack of fetuin-A (α2-HS-glycoprotein) reduces mammary tumor incidence and prolongs tumor latency via the transforming growth factor-β signaling pathway in a mouse model of breast cancer

American Journal of Pathology

Volumn 177, Issue 5, 2010, Pages 2635-2644

  Guillory, Bobby ^a   Sakwe, Amos M ^a   Saria, Margret ^a   Thompson, Pamela ^a   Adhiambo, Christine ^a   Koumangoye, Rainelli ^a   Ballard, Billy ^a   Binhazim, Awadh ^a   Cone, Cecil ^a   Jahanen Dechent, Willi ^b   Ochieng, Josiah ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FETUIN A; PHOSPHATIDYLINOSITOL 3 KINASE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ALPHA2HS GLYCOPROTEIN; PLASMA PROTEIN; VIRUS T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST FIBROSIS; BREAST NECROSIS; CANCER GROWTH; CANCER INCIDENCE; CONTROLLED STUDY; FEMALE; GENOTYPE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL METAPLASIA; ANIMAL; BREAST TUMOR; C57BL MOUSE; DISEASE COURSE; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; BLOOD PROTEINS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 78149286897     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100177     Document Type: Article

References (43)

1. Nie Z: Fetuin: its enigmatic property of growth promotion. Am J Physiol 1992, 263:C551-C562
2. Jahnen-Dechent W, Schinke T, Trindl A, Muller-Esterl W, Sablitzky F, Kaiser S, Blessing M: Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem 1997, 272:31496-31503 (Pubitemid 28013290)
3. Kundranda MN, Henderson M, Carter KJ, Gorden L, Binhazim A, Ray S, Baptiste T, Shokrani M, Leite-Browning ML, Jahnen-Dechent W, Matrisian LM, Ochieng J: The serum glycoprotein fetuin-A promotes Lewis lung carcinoma tumorigenesis via adhesive-dependent and adhesive-independent mechanisms. Cancer Res 2005, 65:499-506
4. Swallow CJ, Partridge EA, Macmillan JC, Tajirian T, DiGuglielmo GM, Hay K, Szweras M, Jahnen-Dechent W, Wrana JL, Redston M, Gallinger S, Dennis JW: α2HS-glycoprotein, an antagonist of transforming growth factor β in vivo, inhibits intestinal tumor progression. Cancer Res 2004, 64:6402-6409
5. 2-HS-glycoprotein and its accumulation in bone. Nature 1976, 262:226-227
6. Brown WM, Saunders NR, Mollgard K, Dziegielewska KM: Fetuin - an old friend revisited. Bioessays 1992, 14:749-755
7. 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003, 112:357-366
8. Spiro RG, Bhoyroo VD: Structure of the O-glycosidically linked carbohydrate units of fetuin. J Biol Chem 1974, 249:5704-5717
9. 2-HS glycoprotein (human fetuin). Evidence for the production of a phosphorylated single-chain form by hepatoma cells. Eur J Biochem 1994, 226:59-69
10. Hendig D, Schulz V, Arndt M, Szliska C, Kleesiek K, Gotting C: Role of serum fetuin-A, a major inhibitor of systemic calcification, in pseudoxanthoma elasticum. Clin Chem 2006, 52:227-234 (Pubitemid 43185483)
11. 2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996, 271:20789-20796
12. 2-HS glycoprotein is a transforming growth factor-β type II receptor mimic and cytokine antagonist. J Biol Chem 1996, 271:12755-12761
13. 2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol 2000, 164:87-98
14. Tiffany JM, Blough HA: The interaction of fetuin with phosphatidylcholine monolayers. Characterization of a lipoprotein membrane system suitable for the attachment of myxoviruses. Biochem J 1970, 117:377-384
15. Cayatte AJ, Kumbla L, Subbiah MT: Marked acceleration of exogenous fatty acid incorporation into cellular triglycerides by fetuin. J Biol Chem 1990, 265:5883-5888 (Pubitemid 20127231)
16. Westenfeld R, Schafer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, Jahnen-Dechent W: Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant 2007, 22:1537-1546 (Pubitemid 47073751)
17. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW: Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003, 163:2113-2126
18. Lomax M, Fried M: Polyoma virus disrupts ARF signaling to p53. Oncogene 2001, 20:4951-4960 (Pubitemid 32769785)
19. Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns A: Simplified mammalian DNA isolation procedure. Nucleic Acids Res 1991, 19:4293
20. Guy CT, Cardiff RD, Muller WJ: Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992, 12:954-961
21. Menes T, Schachter J, Morgenstern S, Fenig E, Lurie H, Gutman H: Primary squamous cell carcinoma (SqCC) of the breast. Am J Clin Oncol 2003, 26:571-573 (Pubitemid 37523058)
22. Malyuchik SS, Kiyamova RG: Medullary breast carcinoma. Exp Oncol 2008, 30:96-101
23. Gold LI: The role for transforming growth factor-β (TGF-β) in human cancer. Crit Rev Oncog 1999, 10:303-360
24. Wakefield LM, Letterio JJ, Geiser AG, Flanders KC, O'Shaughnessy J, Roberts AB, Sporn MB: Transforming growth factor-βs in mammary tumorigenesis: promoters or antipromoters?. Prog Clin Biol Res 1995, 391:133-148
25. Moustakas A, Pardali K, Gaal A, Heldin CH: Mechanisms of TGF-β signaling in regulation of cell growth and differentiation. Immunol Lett 2002, 82:85-91 (Pubitemid 34468039)
26. Shim KS, Kim KH, Han WS, Park EB: Elevated serum levels of transforming growth factor-β1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999, 85:554-561
27. Cordenonsi M, Montagner M, Adorno M, Zacchigna L, Martello G, Mamidi A, Soligo S, Dupont S, Piccolo S: Integration of TGF-β and Ras/MAPK signaling through p53 phosphorylation. Science 2007, 315:840-843 (Pubitemid 46255835)
28. Xirodimas D, Saville MK, Edling C, Lane DP, Lain S: Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 2001, 20:4972-4983
29. Qian Y, Chen X: Tumor suppression by p53: making cells senescent. Histol Histopathol 2010, 25:515-526
30. 2-macroglobulin to its cellular receptor: effect of silencing the CREB gene. J Cell Biochem 2004, 93:1020-1032
31. Derynck R, Akhurst RJ, Balmain A: TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001, 29:117-129 (Pubitemid 32952643)
32. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J: Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003, 100:8430-8435 (Pubitemid 36842562)
33. Barcellos-Hoff MH, Akhurst RJ: Transforming growth factor-β in breast cancer: too much, too late. Breast Cancer Res 2009, 11:202
34. Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL: Transforming growth factor-β regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 2008, 68:1809-1819 (Pubitemid 351416566)
35. Yee KO, Connolly CM, Pines M, Lawler J: Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer Biol Ther 2006, 5:218-224
36. Zhang S, Ekman M, Thakur N, Bu S, Davoodpour P, Grimsby S, Tagami S, Heldin CH, Landstrom M: TGFβ1-induced activation of ATM and p53 mediates apoptosis in a Smad7-dependent manner. Cell Cycle 2006, 5:2787-2795
37. Dupont S, Zacchigna L, Adorno M, Soligo S, Volpin D, Piccolo S, Cordenonsi M: Convergence of p53 and TGF-β signaling networks. Cancer Lett 2004, 213:129-138
38. Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, Piccolo S: Links between tumor suppressors: p53 is required for TGF-β gene responses by cooperating with Smads. Cell 2003, 113:301-314
39. Freeman-Anderson NE, Zheng Y, McCalla-Martin AC, Treanor LM, Zhao YD, Garfin PM, He TC, Mary MN, Thornton JD, Anderson C, Gibbons M, Saab R, Baumer SH, Cunningham JM, Skapek SX: Expression of the Arf tumor suppressor gene is controlled by Tgfβ2 during development. Development 2009, 136:2081-2089
40. Fluck MM, Schaffhausen BS: Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev 2009, 73:542-563
41. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG: Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 2009, 119:252-266
42. Köhrmann A, Kammerer U, Kapp M, Dietl J, Anacker J: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 2009, 9:188
43. Ray S, Lukyanov P, Ochieng J: Members of the cystatin superfamily interact with MMP-9 and protect it from autolytic degradation without affecting its gelatinolytic activities. Biochim Biophys Acta 2003, 1652:91-102